Clinical studies show protective effects of SGLT2 inhibitors on human islet function in type 2 diabetes [3,25], and recently, the treatment was shown to be effective and safe also in type 1 diabetes [21,22], while no study has explored changes in islet composition in relation to function and treatment. Here, SLC5A2 is linked to type 1 diabetes mellitus.